Treasury Yields Set to Stay High as Debt Supply Pressures Bond Market 
Gold Prices Steady as U.S.-Iran Tensions Lift Inflation Risks 
Australia GDP Beats Forecast, Boosting RBA Rate Hike Bets 
Global Markets Brace for Fed Rate Hike as Oil Tops $91 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
China Services PMI Beats Forecasts as Domestic Demand Improves 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
CIA-Linked Investor Helped Quantum Systems Expand in US 
France Targets Shein, Temu With Fast-Fashion Fees 
India Services PMI Rises to 54.1 as Hiring Accelerates 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
US Strikes Iran IRGC Targets as Conflict Escalates 
Asian Currencies Weaken as Dollar Rises, Kiwi Slides After RBNZ Hike 
Asian Currencies Rise as Yen Surges on BOJ Rate Hike Bets 
RBNZ Raises Interest Rate to 2.75%, Kiwi Dollar Slides 
Oil Prices Slip as Trump Eases Iran Supply Fears 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
Add as a preferred source on Google
Celltrion announced that its COVID-19 test kit called DiaTrust has been given conditional approval by South Korea’s drug safety board. The biopharmaceutical company headquartered in Incheon shared the news on Monday, April 3.
The new coronavirus test kit
The Korea Herald reported that DiaTrust was jointly developed by Celltrion and Humasis, an R&D company based in S. Korea as well. The two sides made this antigen test kit that is said to be capable of detecting the newest COVID-19 variants that originated in Brazil and the U.K.
The rapid test kit can show results in as short as 15 minutes. It will identify the particular antigens of coronavirus that are present in the specimen collected from a person through a sterile nasal swab. Celltrion explained that what sets this kit apart from the other of its kind is that it uses a dual antigen method that can spot both N and S antigens.
“Celltrion will speed up its supply of COVID-19 test kit in the domestic market,” a company official stated. “The firm will submit additional clinical data concerning the test kit to the Ministry of Food and Drug Safety within three months.”
The biopharma company is expecting a surge in global demand for the DiaTrust COVID-19 test kit in the near future. In fact, in the U.S., the kit already received emergency use approval from the Food and Drug Administration (FDA). In April, the agency gave its authorization based on the clinical trial results that Celltrion submitted, and it is now reviewing additional clinical data.
Self-test kit to be marketed after gaining FDA nod
Celltrion was granted conditional approval for DiaTrust last week and to get its formal authorization from S. Korea’s Ministry of Food and Drug Safety. It needs to submit more clinical data within three months, as per the Korea Bio Medical Review.
It was added that the company is planning to supply the COVID-19 test kits via its subsidiary firm, Celltrion Pharm. It is also looking at other distribution outlets such as iMarket Korea.
Meanwhile, Celltrion’s new DiaTrust COVID-19 Ag home test kit was said to have shown results with high accuracy. However, it pointed out that suspected coronavirus patients with an obvious epidemiological connection to infection should get PCR tests at authorized screening centers set up by health authorities because the kits are just a supportive tool.
